Physician profile
Maryann Straley
NPI 1780791731
$7,736.99
in general payments reported to CMS, 2019-2025
28 companies · $2,094 in 2025
The $2,094 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $898 · 2022: $1,252 · 2023: $1,700 · 2024: $1,792 · 2025: $2,094.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,457 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,457.21 |
| Education | $129.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,409.97 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $596.80 | 2021-2025 | Odomzo, Blu-U, Winlevi |
| E.R. Squibb & Sons, L.L.C. | $507.70 | 2023-2025 | Sotyktu |
| Pfizer INC. | $465.06 | 2021-2025 | |
| Amgen INC. | $408.82 | 2021-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $398.41 | 2022-2025 | |
| Janssen Biotech, INC. | $396.15 | 2021-2025 | Tremfya, Simponi, Stelara |
| Galderma Laboratories, L.P. | $383.62 | 2021-2025 | Nemluvio, Aklief |
| Ucb, INC. | $353.89 | 2021-2025 | Bimzelx, Cimzia |
| Organon LLC | $343.28 | 2023-2025 | Vtama, Hadlima |
| Genzyme Corporation | $331.60 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $288.41 | 2021-2025 | Dupixent, Libtayo |
| Incyte Corporation | $238.29 | 2021-2024 | Opzelura |
| Dermavant Sciences, INC. | $234.89 | 2023-2024 | Vtama |
| Allergan, INC. | $220.10 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $190.72 | 2021-2025 | Jublia, Cabtreo |
| Arcutis Biotherapeutics, INC. | $188.27 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $174.25 | 2022-2024 | Taltz, Olumiant, Ebglyss |
| Organogenesis INC. | $149.16 | 2022-2024 | Puraply |
| Revance Therapeutics, INC. | $97.36 | 2025 | Daxxify |
| Almirall LLC | $78.00 | 2022-2025 | Klisyri |
| Leo Pharma INC. | $70.11 | 2021-2025 | Anzupgo, Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.24 | 2023-2024 | Spevigo |
| Journey Medical Corporation | $43.93 | 2023-2025 | |
| Vyne Pharmaceuticals INC. | $39.32 | 2021 | |
| Genentech USA, INC. | $33.66 | 2021 | |
| Epi Health, LLC | $30.53 | 2022 | |
| Botanix Sb INC | $18.45 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maryann Straley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.